{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:13:34Z","timestamp":1785464014424,"version":"3.56.0"},"reference-count":21,"publisher":"Akademiai Kiado Zrt.","issue":"34","license":[{"start":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T00:00:00Z","timestamp":1724544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2024,8,25]]},"abstract":"<jats:p><jats:italic>Bevezet\u00e9s:<\/jats:italic> Sz\u00e1mos megfigyel\u00e9s utal arra, hogy bizonyos daganatok\n                    eset\u00e9ben a v\u00e9rk\u00e9p egyes elemei el\u0151re jelzik a beteg t\u00fal\u00e9l\u00e9s\u00e9t.\n                        <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> Prosztatar\u00e1kos betegekn\u00e9l a\n                    neutrophil-lymphocyta ar\u00e1ny (NLR), a thrombocyta-lymphocyta ar\u00e1ny (PLR), a\n                    feh\u00e9rv\u00e9rsejtsz\u00e1m (WBC), illetve a t\u00fal\u00e9l\u00e9si id\u0151 hossza k\u00f6z\u00f6tti kapcsolat\n                    \u00e9rt\u00e9kel\u00e9se. <jats:italic>M\u00f3dszer:<\/jats:italic> Az Uzsoki Utcai K\u00f3rh\u00e1z \u00c1ltal\u00e1nos Urol\u00f3giai\n                    Oszt\u00e1ly\u00e1n 2000 \u00e9s 2005 k\u00f6z\u00f6tt diagnosztiz\u00e1lt prosztatar\u00e1kos betegekn\u00e9l a\n                    klinikai adatok (diagn\u00f3ziskor az \u00e9letkor, a prosztataspecifikus antig\u00e9n [PSA]\n                    szintje, a TNM-pont\u00e9rt\u00e9k, a Gleason-score, t\u00e1rsbetegs\u00e9gek, valamint a v\u00e9rk\u00e9p\n                    elemei) \u00e9s a t\u00fal\u00e9l\u00e9si id\u0151 k\u00f6z\u00f6tti kapcsolat elemz\u00e9se Cox-regresszi\u00f3val.\n                        <jats:italic>Eredm\u00e9nyek:<\/jats:italic> Elemz\u00e9s\u00fcnkben 97 beteg adatait dolgoztuk fel\n                    k\u00e9t \u00e9vtizeddel az ell\u00e1t\u00e1si esem\u00e9ny ut\u00e1n; k\u00f6z\u00fcl\u00fck 82 hunyt el, 15-en m\u00e9g mindig\n                    \u00e9lnek. A prosztatar\u00e1k diagn\u00f3zis\u00e1nak id\u0151pontj\u00e1ban meghat\u00e1rozott v\u00e9rk\u00e9p egyetlen\n                    eleme sem k\u00fcl\u00f6nb\u00f6z\u00f6tt a k\u00e9t csoport (elhunytak \u00e9s t\u00fal\u00e9l\u0151k) k\u00f6z\u00f6tt. A t\u00fal\u00e9l\u00e9si\n                    id\u0151 hossz\u00e1ra a diagn\u00f3zis id\u0151pontj\u00e1ban szignifik\u00e1ns hat\u00e1st csak a beteg \u00e9letkora\n                    (p = 0,004), a PSA-szint (p = 0,033) \u00e9s a Gleason-score (p = 0,033) gyakorolt,\n                    ezeken t\u00fal a v\u00e9rk\u00e9p egyetlen vizsg\u00e1lt param\u00e9tere sem befoly\u00e1solta azt. A\n                    t\u00fal\u00e9l\u00e9si id\u0151 alapj\u00e1n k\u00e9pzett alcsoportokban (1, 2, 5 \u00e9s 10 \u00e9ven bel\u00fcl elhunytak)\n                    sem t\u00e9rtek el a v\u00e9rk\u00e9pparam\u00e9terek. <jats:italic>Megbesz\u00e9l\u00e9s:<\/jats:italic> Az eddig\n                    kor\u00e1bban az irodalomban azonos\u00edtott t\u00e9nyez\u0151k (PSA, Gleason-pont\u00e9rt\u00e9k, \u00e9letkor)\n                    mellett a rutin v\u00e9rk\u00e9p elemei nincsenek kapcsolatban a t\u00fal\u00e9l\u00e9ssel az \u00e1ltal\u00e1nos\n                    prosztatar\u00e1kos popul\u00e1ci\u00f3ban. <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic> Prosztatar\u00e1kban a\n                    v\u00e9rk\u00e9p elemei alapj\u00e1n nem jelezhet\u0151 el\u0151re, hogy a prosztatar\u00e1k diagn\u00f3zis\u00e1t\n                    k\u00f6vet\u0151 \u00e1tlagosan 20 \u00e9v ut\u00e1n melyik az a beteg, aki t\u00fal\u00e9l, illetve hogy az\n                    elhunyt betegek eset\u00e9ben mennyi lesz a t\u00e9nyleges t\u00fal\u00e9l\u00e9si id\u0151 hossza. Orv Hetil.\n                    2024; 165(34): 1319\u20131324.<\/jats:p>","DOI":"10.1556\/650.2024.33082","type":"journal-article","created":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T13:20:48Z","timestamp":1724592048000},"page":"1319-1324","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Prosztatar\u00e1kban a v\u00e9rk\u00e9p a diagn\u00f3zis id\u0151pontj\u00e1ban nem predikt\u00edv a t\u00fal\u00e9l\u00e9sre"],"prefix":"10.1556","volume":"165","author":[{"given":"Zolt\u00e1n","family":"T\u00f3th","sequence":"first","affiliation":[{"name":"Budapesti Uzsoki Utcai K\u00f3rh\u00e1z, Urol\u00f3giai Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Fadgyas-Freyler","sequence":"additional","affiliation":[{"name":"Corvinus Egyetem, Nemzeti Eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si Alapkezel\u0151 Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1kos","family":"Tord\u00e9","sequence":"additional","affiliation":[{"name":"Budapesti Uzsoki Utcai K\u00f3rh\u00e1z, Urol\u00f3giai Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Budapesti Uzsoki Utcai K\u00f3rh\u00e1z, Urol\u00f3giai Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barna","family":"V\u00e1s\u00e1rhelyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Laborat\u00f3riumi Medicina Int\u00e9zet Budapest, Nagyv\u00e1rad t\u00e9r 4., 1089 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Gyarmati","sequence":"additional","affiliation":[{"name":"Budapesti Uzsoki Utcai K\u00f3rh\u00e1z, Sz\u00fcl\u00e9szeti-N\u0151gy\u00f3gy\u00e1szati Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"1 Culp","year":"2020","unstructured":"1 Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020; 77: 38-52.","journal-title":"Eur Urol"},{"key":"ref1","unstructured":"2 International Agency for Research on Cancer-World Health Organization. Data visualization tools for exploring the global cancer burden in 2022. Available from: https:\/\/gco.iarc.fr\/today\/home\/ [access: April 17, 2024]."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3 Rencz F, Brodszky V, Varga P, et al. The economic burden of prostate cancer. A systematic literature overview of registry-based studies. [A prosztatar\u00e1k gazdas\u00e1gi terhe nagy betegregiszterek alapj\u00e1n. Irodalmi \u00e1ttekint\u00e9s.] Orv Hetil. 2014; 155: 509-520. [Hungarian]","DOI":"10.1556\/OH.2014.29837"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4 Riesz P, Nyir\u00e1di P. Novelties in diagnostics and treatment of prostate cancer. [\u00dajdons\u00e1gok a prosztatar\u00e1k diagnosztik\u00e1j\u00e1ban \u00e9s kezel\u00e9s\u00e9ben.] Orv Hetil. 2016; 157: 410-414. [Hungarian]","DOI":"10.1556\/650.2016.30363"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Szarvas T, Csizmarik A, Sz\u0171cs M, et al. Molecular subtypes and perspectives of targeted therapies in prostate cancer. [A prosztatar\u00e1k molekul\u00e1ris alt\u00edpusai \u00e9s c\u00e9lzott ter\u00e1pi\u00e1s kil\u00e1t\u00e1sai.] Orv Hetil. 2019; 160: 252-263. [Hungarian]","DOI":"10.1556\/650.2019.31315"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6 K\u00fcronya Zs, B\u00edr\u00f3 K, G\u00e9czi L, et al. Modern treatment of metastatic hormone-sensitive prostate cancer. [Metasztatikus hormon\u00e9rz\u00e9keny prosztatadaganat korszer\u0171 kezel\u00e9se.] Orv Hetil. 2018; 159: 1664-1671. [Hungarian]","DOI":"10.1556\/650.2018.31218"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"7 Grivennikov","year":"2010","unstructured":"7 Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12885-022-10479-6","article-title":"Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer","volume":"23","author":"8 Zhang","year":"2023","unstructured":"8 Zhang R, Hu C, Zhang J, et al. Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer. BMC Cancer 2023; 23: 5.","journal-title":"BMC Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/JIR.S391932","article-title":"Fashionable, but what is their real clinical usefulness? NLR, LMR, and PLR as a promising indicator in colorectal cancer prognosis: a systematic review","volume":"16","author":"9 Misiewicz","year":"2023","unstructured":"9 Misiewicz A, Dymicka-Piekarska V. Fashionable, but what is their real clinical usefulness? NLR, LMR, and PLR as a promising indicator in colorectal cancer prognosis: a systematic review. J Inflamm Res. 2023; 16: 69-81.","journal-title":"J Inflamm Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/bjs\/znac319","article-title":"Prognostic role of preoperative circulating systemic inflammatory response markers in primary breast cancer: meta-analysis","volume":"109","author":"10 Savioli","year":"2022","unstructured":"10 Savioli F, Morrow ES, Dolan RD, et al. Prognostic role of preoperative circulating systemic inflammatory response markers in primary breast cancer: meta-analysis. Br J Surg. 2022; 109: 1206-1215.","journal-title":"Br J Surg"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11 Yin X, Xiao Y, Li F, et al. Prognostic role of neutrofil-to-lymphocyte ratio in prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2016; 95: e2544.","DOI":"10.1097\/MD.0000000000002544"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"70874","DOI":"10.18632\/oncotarget.20147","article-title":"Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer","volume":"8","author":"12 Wang","year":"2017","unstructured":"12 Wang J, Liu Y, Zhang N, et al. Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer. Oncotarget. 2017; 8: 70874-70882.","journal-title":"Oncotarget"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3892\/ol.2022.13425","article-title":"Role of neutrofil-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio and platelets in prognosis of patients with prostate cancer","volume":"24","author":"13 Huszno","year":"2022","unstructured":"13 Huszno J, Ko\u0142osza Z, Mrochem-Kwarciak J, et al. Role of neutrofil-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio and platelets in prognosis of patients with prostate cancer. Oncol Lett. 2022; 24: 305.","journal-title":"Oncol Lett"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1746-1596-1-4","article-title":"Prognostic factors in prostate cancer","volume":"1","author":"14 Buhmeida","year":"2006","unstructured":"14 Buhmeida A, Pyrh\u00f6nen S, Laato M, et al. Prognostic factors in prostate cancer. Diagn Pathol. 2006; 1: 4.","journal-title":"Diagn Pathol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.juro.2012.01.073","article-title":"Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality","volume":"187","author":"15 Tseng","year":"2012","unstructured":"15 Tseng YD, Chen MH, Beard CJ, et al. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. J Urol. 2012; 187: 2068-2073.","journal-title":"J Urol"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16 Deme D. Prognostic role of neutrofil to lymphocyte ratio determined by complete blood count in malignant diseases. [A v\u00e9rk\u00e9pb\u0151l meghat\u00e1rozott neutrofil-lymphocyta ar\u00e1ny prognosztikai \u00e9rt\u00e9ke daganatos betegs\u00e9gekben.] Orv Hetil. 2022; 163: 1066-1073. [Hungarian]","DOI":"10.1556\/650.2022.32507"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17 Somogyi A, Herold M, Lohinszky J, et al. Survival impact of diabetes and paraneoplastic thrombocytosis in women with breast cancer. [A cukorbetegs\u00e9g \u00e9s a daganatos thrombocytosis t\u00fal\u00e9l\u00e9sre gyakorolt hat\u00e1s\u00e1nak vizsg\u00e1lata eml\u0151tumoros n\u0151kben.] Orv Hetil. 2019; 160: 2012-2020. [Hungarian]","DOI":"10.1556\/650.2019.31594"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18 Herold Z, Ambrus V, Herold M, et al. The occurrence and impact on survival of type 2 diabetes mellitus and thrombocytosis in colorectal cancer, before and after the surgical resection of the primary tumor. [Colorectalis daganatokban a 2-es t\u00edpus\u00fa cukorbetegs\u00e9g \u00e9s a thrombocytosis el\u0151fordul\u00e1sa, a t\u00fal\u00e9l\u00e9sre gyakorolt hat\u00e1suk, a primer tumor m\u0171t\u00e9ti elt\u00e1vol\u00edt\u00e1sa el\u0151tt \u00e9s ut\u00e1n.] Orv Hetil. 2018; 159: 756-767. [Hungarian]","DOI":"10.1556\/650.2018.31038"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19 Szilasi Zs, J\u00f3sa V, Zrubka Z, et al. Elevated platelet count as a possible prognostic marker of survival in patients with head and neck tumours. [A magasabb v\u00e9rlemezkesz\u00e1m mint a fej-nyak tumoros betegek t\u00fal\u00e9l\u00e9ssel kapcsolatos esetleges prognosztikai faktora.] Orv Hetil. 2021; 162: 676-682. [Hungarian]","DOI":"10.1556\/650.2021.32078"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijsu.2018.11.020","article-title":"Prognostic role of neutrofil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: a meta-analysis of results from multivariate analysis","volume":"60","author":"20 Guo","year":"2018","unstructured":"20 Guo J, Fang J, Huang X, et al. Prognostic role of neutrofil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: a meta-analysis of results from multivariate analysis. Int J Surg. 2018; 60: 216-223.","journal-title":"Int J Surg"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/1055-9965.EPI-19-1525","article-title":"Hematologic markers and prostate cancer risk: a prospective analysis in UK Biobank","volume":"29","author":"21 Watts","year":"2020","unstructured":"21 Watts EL, Perez-Cornago A, Kothari J, et al. Hematologic markers and prostate cancer risk: a prospective analysis in UK Biobank. Cancer Epidemiol Biomarkers Prev. 2020; 29: 1615-1626.","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/165\/34\/article-p1319.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/165\/34\/article-p1319.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/165\/34\/article-p1319.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T09:56:44Z","timestamp":1727776604000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/165\/34\/article-p1319.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,25]]},"references-count":21,"journal-issue":{"issue":"34"},"URL":"https:\/\/doi.org\/10.1556\/650.2024.33082","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,25]]}}}